Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ancrod for sudden sensorineural hearing loss
2012-000066-37Phase 2Completed
- Sponsor
- Nordmark Pharma
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute sensorineural hearing loss comparing Ancrod (Viprinex) with Placebo (2 arms). Primary endpoint: Change in pure tone audiogram in affected ear from screening to Day 8. Started Jul 2012; status: completed.
02
Drugs
ancrod
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on 2012-000066-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000066-37.